Key Account Manager - Facial Aesth
About the job
- B.Pharma / M.Pharma / BDS / B.Sc
- 6+ years of Sales experience in pharmaceuticals or healthcare sector with good command over English language and scientific terminology
- Candidate with executive presence, excellent presentation skills and communication skills.
- Deliver sales performance, brand KPIs, financial targets, marketing objectives, etc. in order to meet or exceed on those objectives.
- Create pre-call plan using SMART objectives and execute post-call evaluation in order to continuously improve sales performance.
- Effectively handle objections, misunderstandings, concerns and consistently gain logical and reasonable calls to action in order to close on every sales call.
- Proactively and continuously aspire to serve customer needs, customer expectations and challenges to build trusted customer relationships and to achieve win-win agreements between AbbVie and customers.
- Develop and execute a call plan that achieves set call metrics and optimizes coverage and frequency to key customers to maximize access and sales opportunities.
- Continuously build understanding on customer needs and expectations, territory market landscape, competitors, market segments/dynamics, accounts, disease, product, clinical and sales expertise and share this market intelligence information with in-field team, brand team and sales manager to achieve alignment, to anticipate environmental changes and challenges and to optimize brand strategy and its execution.
- Differentiate AbbVie’s value proposition with health providers assigned and identify, develop and maintain disease state experts and speakers/advocates in order to maximize brand performance.
About the company
AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.
Company Size
10,001+
Company Stage
IPO
Headquarters
North Chicago, Illinois
Founded
1888
Get referred to AbbVie
See people who can refer or advise you
Simplify's Take
What believers are saying
- Apogee acquisition closed in 2026, expanding AbbVie’s immunology pipeline beyond Skyrizi and Rinvoq.
- EU approvals for RINVOQ and EPKINLY in September 2026 broaden ex-U.S. revenue.
- JUVMO launches in October 2026, adding a fresh neuroscience revenue line.
What critics are saying
- Humira, Skyrizi, and Rinvoq concentration keeps AbbVie exposed if immunology growth slows in 2027.
- Niaspan antitrust MDL and Biocell ALCL settlements carried $1.7 billion litigation accrual by June 2026.
- Generic ubrogepant and atogepant suits threaten Ubrelvy and Qulipta exclusivity within years.
What makes AbbVie unique
- Skyrizi and Rinvoq anchor AbbVie’s post-Humira immunology franchise across 11 EU RINVOQ indications.
- JUVMO’s September 28, 2026 FDA approval gives AbbVie first-in-class Parkinson’s D1/D5 therapy.
- AbbVie pairs blockbuster cash flows with Apogee, Iambic, and Valkai deal-making.
Help us improve and share your feedback! Did you find this helpful?
Benefits
- Remote Work Options
- Flexible Work Hours
- Professional Development Budget